Literature DB >> 8626270

In-vitro activity of the fluoroquinolone trovafloxacin against penicillin-susceptible and -resistant Streptococcus pneumoniae.

K Klugman, A Wasas.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1995        PMID： 8626270     DOI： 10.1093/jac/36.5.873

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN： 0305-7453            Impact factor:   5.790


× No keyword cloud information.
  11 in total

1.  In vitro and in vivo antimicrobial activities of T-3811ME, a novel des-F(6)-quinolone.

Authors:  M Takahata; J Mitsuyama; Y Yamashiro; M Yonezawa; H Araki; Y Todo; S Minami; Y Watanabe; H Narita
Journal:  Antimicrob Agents Chemother       Date:  1999-05       Impact factor: 5.191

Review 2.  Trovafloxacin.

Authors:  M Haria; H M Lamb
Journal:  Drugs       Date:  1997-09       Impact factor: 9.546

3.  An open, controlled, crossover study on the effects of cimetidine on the steady-state pharmacokinetics of trovafloxacin.

Authors:  L Purkins; S D Oliver; S A Willavize
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1998-06       Impact factor: 3.267

Review 4.  Epidemiology, control and treatment of multiresistant pneumococci.

Authors:  K P Klugman
Journal:  Drugs       Date:  1996       Impact factor: 9.546

5.  Trovafloxacin, a new fluoroquinolone with potent activity against Streptococcus pneumoniae.

Authors:  K S Thomson; S A Chartrand; C C Sanders; S L Block
Journal:  Antimicrob Agents Chemother       Date:  1997-02       Impact factor: 5.191

6.  Clinical evaluation of the tolerability and efficacy of trovafloxacin compared with sparfloxacin in the treatment of lower respiratory tract infections.

Authors:  J C Shobha; T R Kumar; N Deivanayagam; R B Singh; P Waghray; P A Babu; J Bhaduri; C C Sekhar
Journal:  Clin Drug Investig       Date:  2000       Impact factor: 2.859

7.  Single- and multiple-dose administration, dosing regimens, and pharmacokinetics of trovafloxacin and alatrofloxacin in humans.

Authors:  J Vincent; L Dogolo; B A Baris; S A Willavize; R Teng
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1998-06       Impact factor: 3.267

Review 8.  Bacteriological activity of trovafloxacin, a new quinolone, against respiratory tract pathogens.

Authors:  J C Pechère; T D Gootz
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1998-06       Impact factor: 3.267

9.  Treatment of acute exacerbations of chronic bronchitis: comparison of trovafloxacin and amoxicillin in a multicentre, double-blind, double-dummy study. Trovafloxacin Bronchitis Study Group.

Authors:  B O'Doherty; R Daniel
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1998-06       Impact factor: 3.267

10.  Trovafloxacin versus high-dose amoxicillin (1 g three times daily) in the treatment of community-acquired bacterial pneumonia.

Authors:  F Trémolières; F de Kock; N Pluck; R Daniel
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1998-06       Impact factor: 3.267
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.